 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12...9101112131415161718192021» |
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Sep 19, 2014
P2, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2014 --> Jun 2017
- ||| Enrollment closed: PRECIS: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients (clinicaltrials.gov) - Sep 8, 2014
P2, N=140, Active, not recruiting, Sponsor: Centre Rene Huguenin
Trial primary completion date: Jun 2014 --> Jun 2017 Recruiting --> Active, not recruiting
- Trial primary completion date: Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=80, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2014 --> Jul 2015
- cyclophosphamide / Generic mfg., etoposide IV / Generic mfg., carmustine / Generic mfg.
Trial primary completion date: Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov) - Aug 18, 2014
P=N/A, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Mar 2014 --> Mar 2016
- |||| peripheral blood stem cell transplantation / National Cancer Institute
Trial completion, Enrollment change, Trial initiation date: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 1, 2014
P2, N=69, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2014 --> Mar 2016 Active, not recruiting --> Completed | N=30 --> 69 | Initiation date: Jun 2002 --> Apr 1998
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma (clinicaltrials.gov) - Jul 27, 2014
P2, N=20, Active, not recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Completed | N=30 --> 69 | Initiation date: Jun 2002 --> Apr 1998 Trial primary completion date: Dec 2013 --> Jul 2014
- carmustine / Generic mfg.
Trial primary completion date: O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Jul 21, 2014
P1/2, N=25, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Jul 2014 Trial primary completion date: Jul 2014 --> Apr 2012
- || Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant (clinicaltrials.gov) - Jul 14, 2014
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2014 --> Apr 2012 Trial primary completion date: Feb 2015 --> Feb 2016
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jun 22, 2014
P2, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: May 2015 --> Jun 2014
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment change: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jun 22, 2014
P2, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2015 --> Jun 2014 N=50 --> 30
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion, Enrollment change, Trial primary completion date: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jun 22, 2014
P2, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
N=50 --> 30 Active, not recruiting --> Completed | N=50 --> 30 | Trial primary completion date: May 2015 --> Jun 2014
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial primary completion date, IO biomarker: Autologous Transplant in HIV Patients (BMT CTN 0803) (clinicaltrials.gov) - Jun 1, 2014
P2, N=40, Active, not recruiting, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Completed | N=50 --> 30 | Trial primary completion date: May 2015 --> Jun 2014 Trial primary completion date: Jun 2013 --> May 2015
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 1, 2014
P2, N=101, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Jun 2013 --> May 2015 Trial primary completion date: Jul 2014 --> Jul 2015
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Enrollment closed, IO biomarker: Autologous Transplant in HIV Patients (BMT CTN 0803) (clinicaltrials.gov) - Jun 1, 2014
P2, N=40, Active, not recruiting, Sponsor: Medical College of Wisconsin
Trial primary completion date: Jul 2014 --> Jul 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma (clinicaltrials.gov) - May 14, 2014
P2, N=300, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2013 --> Aug 2014
- Trial initiation date: Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma (clinicaltrials.gov) - May 14, 2014
P2, N=300, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Aug 2013 --> Aug 2014 Initiation date: Nov 2005 --> Aug 2005
- Enrollment change: Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma (clinicaltrials.gov) - May 14, 2014
P2, N=300, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Initiation date: Nov 2005 --> Aug 2005 N=150 --> 300
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: MasterPlan: Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma (clinicaltrials.gov) - May 8, 2014
P2, N=29, Completed, Sponsor: St. Louis University
N=150 --> 300 Trial primary completion date: Aug 2016 --> Jun 2012
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion date: MasterPlan: Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma (clinicaltrials.gov) - May 8, 2014
P2, N=29, Completed, Sponsor: St. Louis University
Trial primary completion date: Aug 2016 --> Jun 2012 Trial completion date: Jul 2026 --> Jun 2012
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment change: MasterPlan: Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma (clinicaltrials.gov) - May 8, 2014
P2, N=29, Completed, Sponsor: St. Louis University
Trial completion date: Jul 2026 --> Jun 2012 N=50 --> 29
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion: MasterPlan: Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma (clinicaltrials.gov) - May 8, 2014
P2, N=29, Completed, Sponsor: St. Louis University
N=50 --> 29 Recruiting --> Completed
- Trial initiation date: Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (clinicaltrials.gov) - May 1, 2014
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Initiation date: Feb 2014 --> Mar 2014
- Trial completion date: Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (clinicaltrials.gov) - May 1, 2014
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Feb 2014 --> Mar 2014 Trial completion date: May 2016 --> Mar 2016
- Trial primary completion date: Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (clinicaltrials.gov) - May 1, 2014
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: May 2016 --> Mar 2016 Trial primary completion date: May 2014 --> Mar 2015
- Enrollment open: Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (clinicaltrials.gov) - May 1, 2014
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: May 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- vadacabtagene leraleucel (JCAR015) / BMS
Enrollment open: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 20, 2014
P1, N=18, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Suspended --> Recruiting
- carmustine / Generic mfg.
Enrollment closed: O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Mar 31, 2014
P1/2, N=28, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed: Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=75, Active, not recruiting, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment change: Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 26, 2014
P2, N=60, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting N=85 --> 60
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 19, 2014
P2, N=44, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=85 --> 60 Completed --> Active, not recruiting
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change: CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies (clinicaltrials.gov) - Mar 6, 2014
P1, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting N=30 --> 60
- | Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Trial completion, Immunomodulating: Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=24, Completed, Sponsor: Children's Oncology Group
N=30 --> 60 Active, not recruiting --> Completed
- ||||||| lomustine / Generic mfg., temozolomide / Generic mfg., carmustine / Generic mfg.
Trial completion: Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Feb 22, 2014
P3, N=118, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion: Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P1, N=44, Completed, Sponsor: Northwestern University
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Post-transplantation: Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=0, Completed, Sponsor: University of Maryland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=37, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | cytarabine / Generic mfg.
Trial completion: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=30, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=30, Completed, Sponsor: Herbert Irving Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion, Metastases: O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion: Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=48, Completed, Sponsor: New Approaches to Brain Tumor Therapy
No longer recruiting --> Completed Recruiting --> Completed
- | temozolomide / Generic mfg., carmustine / Generic mfg.
Trial completion: Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 19, 2014
P2, N=22, Completed, Sponsor: University of Maryland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=80, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zanosar (streptozocin) / Teva
Trial completion, Metastases: Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=18, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery, Metastases: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=32, Completed, Sponsor: University of Maryland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | melphalan / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion: Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 19, 2014
P2, N=35, Completed, Sponsor: University of Maryland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion: Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=25, Completed, Sponsor: University of Maryland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=80, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed